| Metric | Value (₹ Cr) | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue | 224.29 | 0.0% | 15.3% |
| Total Income | 226.53 | 0.3% | 15.2% |
| Expenditure | 157.13 | 0.1% | 11.9% |
| PBT | 69.40 | 0.6% | 0.3% |
| Net Profit | 52.10 | 3.4% | 6.0% |
| OPM | 34.34% | 3.35pp | |
| NPM | 23.00% | 0.82pp | 5.18pp |
| EPS | 30.70 | 3.4% | 6.0% |
Margin strength masks sequential revenue flatness; growth timing-dependent
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
FY'27 EBITDA floor raised ₹300→₹310 Cr; FY'28 targets (₹1,500 Cr revenue) unchanged from Q1. Margin guidance hit, but organic growth softer.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Margin expansion to 34.3% (highest recent) validates operational leverage thesis and FY'27 EBITDA floor raised to ₹310 Cr. However, sequential revenue flat at 0% QoQ and PAT down 6% YoY despite margin strength signals execution risk in organic growth and mandate timing. Multi-year Rule of 50 roadmap is credible but dependent on US adoption cycle acceleration in H2.
₹224.3 Cr
Revenue · +15.4% YoY₹52.1 Cr
Reported PAT · −6% YoYExpanding
Margins · vs guidance: CorroboratedDid the claims hold up?
Most profitable half-year in history; EBITDA grew 39% YoY
METH1 revenue 448.5 Cr (+17.8% YoY); Q2 margin 34.3%, highest recent history; PAT -6% YoY due to prior-year one-time gain
Second quarter in a row above 34% EBITDA margin
METQ2 OPM delivered 34.3%, consistent with claim
Top 5 clients fell from 51% to 46% of revenue
METDiversification metric cited but not independently verified; consistent with reported trend
Research outside AJE grew 22% this quarter with no acquisition
METOrganic research growth 22% corroborates organic momentum; AJE still integrating
Zero debt, 163 Cr cash on Sept 30
METStrong balance sheet claim; DSO improved to 38 days from 45; Unbound debt repaid in full
Earnings quality
What changed since the last call
FY'27 EBITDA floor raised
Upgrade₹300 Cr → ₹310 Cr; 34.3% margin delivery in Q2 above prior implied guidance
Rule of 50 progress slowing
DowngradeQ1 FY'27 achieved 54 (20% revenue + 34% margin); Q2 shows 0% sequential revenue, indicating near-term growth pressure
Research organic growth outside AJE
Neutral22% growth in research excluding AJE, offset by timing in education/CL; sequential overall 0%
Customer diversification
UpgradeTop 5 clients fell from 51% to 46%; customer base expanded 839 billings vs. 422 prior year
The Q&A
Analysts pressed hard on organic growth gap (22% research vs. 0% sequential overall), AJE post-acq struggles, and FY'28 guidance unchanged despite margin strength. Management held firm on timing variability (education/CL adoption cycles), Rule of 50 levering through, and acquisition pipeline; defended organic research momentum 22% and Unbound/AJE strategic fit. Tone grew defensive on near-term, not defensive on strategy.
Revenue growth deceleration — Navid, Bastion Research
PartialTiming issue: education and CL adoption cycles don't run straight-line Q-to-Q; Q2 mandates start Nov-Dec billing. H2 expected stronger. Next acquisition closing FY'27.
Acquisitions pipeline — Navid, Bastion Research
Partial₹1,500 Cr always combined organic + M&A. Next deal expected this FY; ₹310 Cr EBITDA floor shows confidence. Pipeline active, walking away on price discipline.
Organic growth variability — Harsh Sharma, Investor
AnsweredResearch revenue timing Q2 hit, larger mandates won start Nov-Dec billing; education/CL move with US adoption and project cycles. No change in plan. H2 expected stronger.
Niche acquisition criteria — Navid, Bastion Research
AnsweredTemplate: AI tailwinds, low customer concentration, recurring revenue, defensible niche (Unbound model). Science/high-stakes content required. Balance sheet strong; zero debt, ₹163 Cr cash.
Political risk – US funding — Vaibhav Agarwal, Investor
AnsweredCongress stability favors NIH/NSF funding (Deep cuts less likely; nursing programs protected under Democratic majority). Education policy supports school adoption programs; accessibility rules a tailwind. Customers value predictability.
Education organic growth — Rahul, Dolat Capital
PartialUS adoption calendar (Florida → California): order booking this Q, revenue flows Q4 onwards. Larger mandates won; still order-booking stage, not yet billing.
AJE payback and strategy — Navid, Bastion Research
AnsweredAJE payback 2–2.5 years, likely done in 3rd full year. Margins improving (12-13% acq → 18% now). Pre-submission peer review live (Apr), new integrity mandate (Nov), more author solutions by FY'27-end. Unbound/AJE synergy unlocking new customers.
Corporate Learning healthcare workforce — Rahul, Dolat Capital
AnsweredUnbound owns content + platform; healthcare systems use MPS + Liberate for nurse training at colleges → hospitals. Core macro problem: USD 60K nurse replacement cost. MPS reducing churn via companion app. Market durable multi-year; APAC also growing, AI adoption driving more training.
ROCE and acquisition returns — Navid, Bastion Research
AnsweredROCE continues to expand despite acquisitions; high-return assets like AJE lifting overall. Next acquisition vets same template (Unbound model). Discipline on price prevents dilution. We're expanding, not optimizing down.
Contract lifecycle and pricing — Manan, MKP Securities
AnsweredContracts 3-5 years; long-term typically; win format. Pricing: volume absorbs cost growth (win-format + AI speed = higher productivity). Pricing not a primary lever; throughput is. SG&A up but EBITDA margin expanding = operating leverage.
Guidance
FY'28 ₹1,500 Cr revenue (from Q1 call, reaffirmed)
MediumQ2 ARR ~224 Cr × 4 = ~896 Cr; 1,500 Cr implies 67% growth over 1.5yr (42% CAGR); contingent on US education adoption cycle H2 billing, acquisitions
FY'27 EBITDA ≥₹310 Cr (raised from ₹300 Cr floor)
HighQ2 delivered 34.3% margin; H1 EBITDA 154 Cr; implies full-year EBITDA ~308–310 Cr at current pace
Growth capex + acquisitions priority; ₹1 Cr+ capex possible if Unbound integration continues
LowNo explicit capex guidance; focus on platform/IP/AI investments; capital discipline on M&A pricing
Risks the call surfaced
Timing/Order Book Execution
HighNew US education mandates won (Florida math adoption, California follows) start billing Nov–Dec. If timing slips to FY'28, H2 FY'27 revenue flat, full-year growth target ~15% could miss.
Customer Concentration
MediumTop 5 clients still 46% of revenue (down from 51% but elevated). Research concentrated in US academia; Corporate Learning in US healthcare. Policy changes (NIH funding, nursing programs) materially affect demand.
Organic Growth vs. Organic Acquisition Mix
MediumH1 shows 17.8% revenue growth, but Q2 was 0% sequential and 15.4% YoY. Organic growth in research 22% (ex-AJE) but timing in education/CL bunched. FY'28 ₹1,500 Cr target implies 40%+ CAGR if organic growth stays ~20%; requires either acceleration or ₹300+ Cr acquisition.
AJE Integration & Post-Acq Execution
MediumAJE (AI language editing) acquired but organic growth disappointing post-deal. Payback period 2–2.5 years (end FY'28). Margins improving (12-13% → 18%) but new customer doors and author solutions still launching (Nov, FY'27-end). Delay in customer acquisition could extend payback or miss FY'28 EBITDA targets.
Macro/Policy Risk – US Federal Funding & Healthcare
LowRepublican administration historically proposed cutting NIH budget by 20-40%; Congress has rejected in past. Democratic control (post-Nov 2024 election) now favors research/education/nursing funding. However, longer-term risk if control shifts. Healthcare nursing shortage core problem (USD 60K replacement cost) but Unbound/Liberate solutions dependent on hospital adoption velocity.
Management
Score 7/10. Clear and structured (3-segment walkthrough, financial metrics, outlook). Transparent on timing variability in education/CL. Less transparent on AJE growth softness; glossed over organic growth vs. sequential gap. Strong track record: 11 acquisitions in 13 years, 650+ Cr shareholder returns, Rule of 50 achieved (54 in Q1). Q2 margin guidance hit (34.3%). FY'27 EBITDA floor raised (₹310 Cr). But organic revenue growth softening (0% QoQ, 15.4% YoY vs. H1 17.8%), raising execution questions.
1 · Nov–Dec 2026
US school adoption cycle mandates begin; H2 revenue front-loaded to Q4
2 · FY'27 end (Mar 2027)
Next acquisition expected to close; target ₹1,500 Cr FY'28 revenue
3 · H2 FY'27
Unbound/Liberate healthcare platform expansion; corporate learning AI adoption scaling
Multi-year Rule of 50 roadmap is credible but dependent on US adoption cycle acceleration in H2.
Margin Peak Masks Growth Timing Risk
Operating leverage thesis proved out — EBITDA margin reached 34.3%, highest on record, and the FY'27 floor was raised to ₹310 Crore. But sequential revenue was flat at 0% despite new mandate wins, concentrating all growth into a narrower H2 window. The real number to track: whether November and December actually deliver.
₹224.3 Cr
+15.4% YoY, 0% QoQ
34.3%
highest recent; 2nd quarter >34%
₹52.1 Cr
-6% reported (distorted by prior one-time)
~+22%
current vs adjusted prior
The headline looks weak: profit down 6% year-over-year despite the highest operating margin in recent history. But the gap between reported and organic profit is the quarter's real story. Q2 FY'26 carried a ₹12.8 crore one-time write-back on Liberate, the clinical learning platform acquired as part of Unbound; strip that out, and organic PAT growth is roughly +22%. What the quarter actually delivered was margin — and the market saw it. The FY'27 EBITDA floor was raised from ₹300 crore to ₹310 crore, a tacit upgrade. The problem is what it masks: revenue was completely flat quarter-on-quarter, a 0% sequential, despite management claiming new large mandates in education and corporate learning were closed this quarter.
The margin thesis holds. The growth thesis doesn't—yet.
Operating leverage is the centerpiece of MPS's playbook. The Rule of 50—a venture-backed proxy for durability, calculated as growth rate plus operating margin—hit 54 in Q1 (20% growth + 34% margin). Management aspires for that to hold through the year. Q2 proves the margin half: 34.3% operating margin, the highest MPS has delivered in recent quarters, and the second time in a row above 34%. That level isn't a one-time performance; it reflects real cost discipline and scale. H1 EBITDA of ₹154 crore, if annualized at the same pace, lands at roughly ₹308–310 crore, which squares with the raised floor. So the margin upgrade is credible.
But the growth half of the Rule fell apart. Q2 revenue of ₹224.3 crore is +15.4% year-over-year, which looks healthy in isolation. But sequentially—comparing Q2 to Q1—it's a flat 0%. That's where the tension lives. Management said on the call that large education mandates (US state curriculum adoptions in Florida and California) and corporate learning contracts (healthcare workforce training via the Unbound/Liberate platform) were signed in Q2. Yet sequential revenue didn't budge. The answer, per management, is timing: these mandates have order-booked now, but won't start billing until November and December. H2, they assure, will be weighted heavily to Q4 as a result.
That's plausible on the face of it. School board cycles and healthcare procurement do run on calendars, not straight lines. But there's a secondary risk: if those Nov–Dec mandates slip even modestly—a delayed procurement sign-off, a budget-cycle hold, a customer's internal prioritization shift—Q3 will also be flat, and the full-year growth target (implied ~15% by the unchanged FY'28 guidance) could miss. The stock's market reaction has already priced in this anxiety.
Most profitable H1 in history; EBITDA grew 39% YoY
H1 revenue +17.8% YoY; Q2 margin 34.3% (highest recent). PAT -6% YoY due to ₹12.8 Cr prior one-time.
Supported
Second consecutive quarter above 34% EBITDA margin
Q2 OPM delivered 34.3%, consistent with claim. Operating leverage thesis validated.
Supported
Top 5 clients fell from 51% to 46% of revenue
Diversification improving. Client count billed rose to 839 vs. 422 prior year.
Supported
Organic research growth 22% this quarter, no acquisition
Research revenue ex-AJE grew 22%, corroborating organic momentum outside integration.
Supported
Large education and CL mandates won; will invoice Nov–Dec
Order book strong; education H1 grew 36%. Q2 revenue sequential flat. Timing is the lynchpin—not contradicted, but unproven.
Plausible, not yet realized
What changed on this call
FY'27 EBITDA floor raised ₹300 Cr → ₹310 Cr
Rule of 50 slowing: Q2 shows 0% seq. revenue vs. 54 in Q1
Customer diversification improving: top 5 fell from 51% to 46%
FY'28 guidance unchanged: ₹1,500 Cr revenue, ₹450 Cr EBITDA
Organic research outside AJE: 22% growth, offsetting weaker education/CL timing
AJE margins improving (12–13% acq. → 18% now), but organic growth soft
The bull case, the bear case, the honest read
The street's take—where the stock sits
MPS closed at ₹2,242 on November 9, down 27% from its all-time high of ₹3,079. It's below its 20-day (₹2,354) and 50-day (₹2,523) moving averages, but above its 200-day average (₹2,067). RSI is 39.2, approaching oversold but not yet there. Volume is normal, suggesting the decline is fundamental repricing, not panic.
Ownership has shifted. Foreign institutional investors (FII) trimmed from 1.47% to 1.38% quarter-over-quarter. Domestic institutional investors (DII) added, rising from 1.96% to 2.14%. Promoter stake remains locked at 68.34%. This is the classic FII-exiting-macro-anxiety / DII-accumulating-on-valuation pattern. Foreign investors are hedging India cyclical risk; domestic investors view the drawdown as an entry point.
That squares with fundamentals. Margin is undeniable; foreigners aren't exiting because unit economics deteriorated. They're exiting because the stock has run 67% off its 52-week low and growth—the justification for that multiple—is now conditional on Nov–Dec mandate realization. That's fair risk-off for a 27% drawdown. The question is whether the drawdown is buying the right pessimism.
Ranked risks—what matters most to a holder
H2 mandate timing slips
HighIf Nov–Dec education and CL billing delays, Q3 will also be flat and FY'27 growth target could miss. This is the near-term binary; market is pricing it in.
Sequential flatness signals execution or capacity constraint
HighIf 0% QoQ growth persists beyond Q2, it suggests structural scaling constraint, not timing issue. Would flatten growth guidance significantly.
AJE payback extends beyond FY'28
MediumAJE's new customer doors aren't materializing as fast as expected (organic research 22% ex-AJE implies AJE near-zero). If payback extends, FY'28 EBITDA accretion is delayed.
Customer concentration remains elevated at 46% top 5
MediumEducation and healthcare policy shifts (NIH budget cuts, school funding cycles) could materially affect demand. Healthcare nursing shortage could soften Unbound adoption if it slows.
FY'28 guidance unchanged despite raised FY'27 floor
MediumManagement raised FY'27 to ₹310 Cr but kept FY'28 at ₹1,500 Cr revenue unchanged from Q1. Signals confidence gap between near-term and medium-term.
1 · Q3 revenue—is Nov–Dec mandate timing real or aspirational?
If Q3 sees sequential growth inflection (>5% would be meaningful), the Nov–Dec timing narrative holds and H2 concentration is proven. If Q3 is also flat or negative, the growth thesis cracks. This is the critical near-term test.
2 · AJE customer door wins and payback trajectory
New customer solutions (pre-submission peer review, integrity mandate, author offerings) are supposed to unlock new doors by end of FY'27. The ₹70+ crore payback depends on this. Watch FY'28 guidance for evidence—if AJE is still a drag, payback extends and acquisition track record is dinged.
3 · FY'28 guidance reset—does ₹1,500 Cr revenue target get adjusted?
₹1,500 Cr implies 40%+ CAGR from implied ₹900 Cr annualized run-rate. Aspirational if organic stays ~20%. Management will likely adjust downward or announce major acquisition. If unchanged through FY'27-end, that's a bold bet.
The verdict
MPS has proven its margin thesis: 34.3% operating margin, the highest in recent history, is no fluke. It reflects real operating leverage and discipline. The FY'27 EBITDA floor, raised to ₹310 crore, will likely hold.
But the growth thesis is now conditional. Sequential revenue flat at 0% despite mandate wins means all the year's growth is bunched into a narrower window (H2, weighted to Q4). That concentration is manageable if Nov–Dec timing holds; it's a significant miss if it doesn't. The market has already priced in this anxiety: stock down 27% from all-time high, foreign investors trimming, valuation at a discount to recent history.
Steady margin execution, but growth timing deteriorating. Not a collapse, not a growth story anymore. This is a "show-me" quarter. The number to track: H2 sequential growth. If Q3–Q4 deliver the mandated timing, the stock rebounds. If they don't, FY'28 guidance gets reset and the multiple compresses further. Margin strength alone doesn't sustain a growth multiple; MPS needs to prove growth is real, not just delayed.